Objective:To evaluate the influence of epilepsy and antiepileptic drugs on bone mineral density(BMD) and bone metabolism in children with epilepsy. Methods:A retrospective analysis was carried out on 150 children with epilepsy. The children were divided into untreated group(n=50), VPA1 group(n=35), LEV1 group(n=33) and OXC1 group(n=32). Fifty normal children were selected as control group. The influence of epilepsy itself and antiepileptic drugs on BMD and bone metabolism was retrospectively analyzed. A prospective study was carried out on 100 pre-school age and 100 school age epileptic children, who were randomly divided into three groups,i.e., 33 in VPA2 and VPA3 group,34 in LEV2 and LEV3 group, 33 in OXC2 and OXC3 group. After 3, 6 and 12 months, BMD and bone metabolism were observed. Results:In the retrospective study, there were statistically differences in BMD and calcium, of which the untreated group and other three groups were lower than those of normal children(P<0.05), and VPA group was the lowest. In the prospective study, after treatment in pre-school age children for 3, 6 and 12 months, there were statistically differences in BMD and calcium, of which VPA2 group was lower than those of LEV2 group and OXC2 group(P<0.05).And bone alkaline phosphatase(BAP) of VPA2 group was higher than those of LEV2 group and OXC2 group(P<0.05).After treatment in school age children for 12 months, there were statistically differences in BMD and calcium, of which the VPA3 group was lower than those of LEV3 group and OXC3 group(P<0.05). And BAP was higher than those of LEV3 group and OXC3 group(P<0.05). Conclusion:Epilepsy itself affects BMD and bone metabolism in children. The influences of VPA on BMD and bone metabolism are increased with the course of treatment. However, LEV and OXC have no significant effect on BMD and bone metabolism, which is worth promoting in clinical practice.
 PITETZIS D A,SPILIOTI M G,YOVOS J G,et al.The effect of VPA on bone:from clinical studies to cell cultures-the molecular mechanisms revisited[J].Seizure,2017,48:36-43.
 YILDIZ E P,POYRAZOGLU S,BEKTAS G,et al.Potential risk factors for vitamin D levels in medium-and long-term use of antiepileptic drugs in childhood[J].Acta Neurol Belg,2017,117(2):447-453.
 ENGEL J.Report of the ILAE classification core group[J].Epilepsia,2010,47(9):1558-1568.
 FONG C Y,KONG A N,NOORDIN M,et al.Determinants of low bone mineral density in children with epilepsy[J].Eur J Paediatr Neurol,2018,22(1):155-163.
 DUSSAULT P M,LAZZARI A A.Epilepsy and osteoporosis risk[J].Curr Opin Endocrinol Diabetes Obes,2017,24(6):395-401.
 HAMED S A,MOUSSA E M,YOUSSEF A H,et al.Bone status in patients with epilepsy:relationship to markers of bone remodeling[J].Front Neurol,2014,5:142.
 MIRATASHI-YAZDI S A,ABBASI M,MIRATASHI-YAZDI S M.Epilepsy and vitamin D:a comprehensive review of current knowledge[J].Rev Neurosci,2017,28(2):185-201.
 NAKHAEE M M,TEIMOUR A,KHAJEH A,et al.Bone metabolism disorder in epileptic children[J].Iran J Child Neurol,2018,12(2):17-24.
 SINGLA S,KAUSHAL S,ARORA S,et al.Bone health in patients with epilepsy:a community-based pilot nested case-control study[J].Ann Indian Acad Neurol,2017,20(4):367-371.
 HUMPHREY E L,MORRIS G E,FULLER H R.Valproate reduces collagen and osteonectin in cultured bone cells[J].Epilepsy Res,2013,106(3):446-450.
 JENSEN E D,SCHROEDER T M,BAILEY J,et al.Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner[J].Bone Miner Res,2008,23(3):361-372.
 PERUCCA E.Clinically relevant drug interactions with antiepileptic drugs[J].Br J Clin Pharmacol,2006,61(3):246-255.
 VRZAL R,DORICAKOVAA A,NOVATNA A,et al.Valproicacid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3:a possible cause of valproic acid-induced osteomalacia?[J].Toxicol Lett,2011,200(3):146-153.
 VERROTTI A,LOIACONO G,LAUS M,et al.Hormonal and reproductive disturbances in epileptic male patients:emerging issues[J].Reprod Toxicol,2011,31(4):519-527.